About this FactMed analysis covering adverse side effect reports of ALMARL patients who developed CONVULSION.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 5 individuals taking ALMARL reported CONVULSION to the FDA. A total of 227 ALMARL drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between ALMARL and CONVULSION. In doing so, we compare ALMARL with other drugs that cause CONVULSION, to help you evaluate whether or not ALMARL causes CONVULSION. Likewise, this page shows the most highly-reported side effects of ALMARL, so you can see if CONVULSION ranks among ALMARL's most well-known side effects.
Summary Statistics
Reports of ALMARL causing CONVULSION: 5
Reports of any side effect of ALMARL : 227
Percentage of ALMARL patients where CONVULSION is a reported side effect: 2.2026%

FDA reports of any drug causing CONVULSION : 64904
Average percentage for all medicated patients where CONVULSION is reported as a complication: 0.4068%

Physician opinion on ALMARL as adverse event culprit:

Overall opinion for all reports of this drug:
Most frequent diagnoses/indications for prescribing ALMARL:
HYPERTENSION ( 76 patients )
PARKINSON'S DISEASE ( 8 patients )
ESSENTIAL TREMOR ( 6 patients )
ATRIAL FIBRILLATION ( 4 patients )
SCHIZOPHRENIA ( 2 patients )
TREMOR ( 2 patients )
ANGINA PECTORIS ( 2 patients )
DRUG USE FOR UNKNOWN INDICATION ( 2 patients )
PALPITATIONS ( 2 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 2 patients )
TACHYCARDIA ( 2 patients )
HYPERTROPHY ( 1 patients )
( 0 patients )
Drugs with high FDA adverse event association with CONVULSION:

SEROQUEL (4060 patients)
KEPPRA (3407 patients)
DILANTIN (3088 patients)
VIOXX (3003 patients)
AVONEX (2696 patients)
ASPIRIN (2681 patients)
LAMICTAL (2451 patients)
TEGRETOL (2091 patients)
NEURONTIN (1865 patients)
TYSABRI (1804 patients)
TOPAMAX (1640 patients)
LYRICA (1638 patients)
LAMOTRIGINE (1551 patients)
DEPAKOTE (1526 patients)
XANAX (1387 patients)
REBIF (1339 patients)
TRILEPTAL (1319 patients)
ZOLOFT (1317 patients)
PAXIL (1297 patients)
PHENYTOIN (1297 patients)
WELLBUTRIN (1291 patients)
LEXAPRO (1276 patients)
LIPITOR (1265 patients)
CLONAZEPAM (1236 patients)
CYMBALTA (1223 patients)
OMEPRAZOLE (1219 patients)
FOSAMAX (1205 patients)
CARBAMAZEPINE (1182 patients)
LEVETIRACETAM (1168 patients)
PREDNISONE (1167 patients)
CHANTIX (1140 patients)
VALPROATE SODIUM (1136 patients)
ACETAMINOPHEN (1114 patients)
SYNTHROID (1111 patients)
NEXIUM (1096 patients)
FOLIC ACID (1062 patients)
ZYPREXA (1042 patients)
METHOTREXATE (1029 patients)
LASIX (1028 patients)
LORAZEPAM (997 patients)
LISINOPRIL (984 patients)
KLONOPIN (969 patients)
RISPERDAL (967 patients)
CLOZARIL (966 patients)
HEPARIN SODIUM INJECTION (933 patients)
GABAPENTIN (930 patients)
ATIVAN (916 patients)
DEPAKENE (873 patients)
ATENOLOL (865 patients)
TOPIRAMATE (857 patients)
AMBIEN (847 patients)
DIAZEPAM (829 patients)
BACLOFEN (817 patients)
IBUPROFEN (801 patients)
TRAMADOL HCL (795 patients)
SIMVASTATIN (794 patients)
LEVOTHYROXINE SODIUM (785 patients)
FUROSEMIDE (781 patients)
SUBOXONE (775 patients)
ALBUTEROL (748 patients)
PROZAC (746 patients)
PLAVIX (743 patients)
EFFEXOR (742 patients)
REMICADE (737 patients)
PREDNISOLONE (733 patients)
PHENOBARBITAL TAB (730 patients)
DEXAMETHASONE (715 patients)
NORVASC (709 patients)
HUMIRA (698 patients)
COUMADIN (692 patients)
LANTUS (688 patients)
VICODIN (683 patients)
ABILIFY (658 patients)
PROTONIX (652 patients)
HYDROCHLOROTHIAZIDE (649 patients)
VALPROIC ACID (645 patients)
PREVACID (636 patients)
ZOCOR (636 patients)
OXYCONTIN (634 patients)
PRILOSEC (620 patients)
BETASERON (608 patients)
FORTEO (600 patients)
DURAGESIC-100 (592 patients)
SINGULAIR (591 patients)
CITALOPRAM HYDROBROMIDE (585 patients)
EFFEXOR XR (584 patients)
TRAZODONE HCL (584 patients)
TOPROL-XL (582 patients)
POTASSIUM CHLORIDE (576 patients)
DECADRON (571 patients)
VALIUM (566 patients)
VITAMIN D (564 patients)
CELEBREX (563 patients)
DIGOXIN (554 patients)
INSULIN (547 patients)
ULTRAM (528 patients)
CYCLOPHOSPHAMIDE (522 patients)
CLOZAPINE (516 patients)
ZOFRAN (513 patients)
CYCLOSPORINE (513 patients)
MORPHINE (513 patients)
VIMPAT (512 patients)
PREDNISONE TAB (506 patients)
ENBREL (505 patients)
PROGRAF (500 patients)
ZOMETA (499 patients)
ALPRAZOLAM (486 patients)
CELEXA (483 patients)
PERCOCET (483 patients)
FENTANYL (478 patients)
MIRTAZAPINE (477 patients)
OXCARBAZEPINE (476 patients)
DIOVAN (474 patients)
ARICEPT (463 patients)
WARFARIN SODIUM (462 patients)
METFORMIN HCL (452 patients)
LEVAQUIN (450 patients)
AMITRIPTYLINE HCL (449 patients)
ZYRTEC (446 patients)
AMPYRA (445 patients)
BENADRYL (431 patients)
HALDOL (430 patients)
DIANEAL (428 patients)
METOPROLOL TARTRATE (418 patients)
AMLODIPINE (417 patients)
ZANTAC (416 patients)
TYLENOL (CAPLET) (411 patients)
YASMIN (409 patients)
CALCIUM (406 patients)
CLONIDINE (404 patients)
LORTAB (403 patients)
HUMALOG (403 patients)
LIORESAL (403 patients)
CRESTOR (402 patients)
ALLOPURINOL (402 patients)
WELLBUTRIN XL (401 patients)
AVASTIN (401 patients)
STRATTERA (400 patients)
MULTI-VITAMINS (396 patients)
MULTI-VITAMIN (392 patients)
LOVENOX (390 patients)
GEODON (385 patients)
ACCUTANE (385 patients)
GABITRIL (384 patients)
LANSOPRAZOLE (382 patients)
PAROXETINE HCL (381 patients)
PROVIGIL (375 patients)
LACOSAMIDE (372 patients)
SEROQUEL XR (370 patients)
ADVAIR DISKUS 100/50 (369 patients)
YAZ (364 patients)
NITROGLYCERIN (362 patients)
OXYCODONE HCL (360 patients)
RIBAVIRIN (360 patients)
DILANTIN-125 (360 patients)
TYLENOL (360 patients)
PHENYTOIN SODIUM (360 patients)
PEGASYS (359 patients)
AMOXICILLIN (356 patients)
CISPLATIN (355 patients)
FLUOXETINE (354 patients)
CYTARABINE (353 patients)
RISPERIDONE (353 patients)
ACYCLOVIR (352 patients)
RANITIDINE (349 patients)
REGLAN (348 patients)
BACTRIM (345 patients)
METHYLPREDNISOLONE (344 patients)
PRIMAXIN (344 patients)
TAMIFLU (342 patients)
ZONISAMIDE (339 patients)
REVLIMID (337 patients)
COPAXONE (336 patients)
CIPROFLOXACIN (331 patients)
PREMARIN (330 patients)
NAMENDA (325 patients)
ZONEGRAN (325 patients)
FAMOTIDINE (323 patients)
RAMIPRIL (323 patients)
ALL OTHER THERAPEUTIC PRODUCTS (321 patients)
NEORAL (320 patients)
FLEXERIL (319 patients)
METHADONE HCL (319 patients)
SOLU-MEDROL (314 patients)
ALLEGRA (312 patients)
AVELOX (311 patients)
PROPRANOLOL (310 patients)
VANCOMYCIN (310 patients)
GILENYA (308 patients)
FLUOROURACIL (306 patients)
PANTOPRAZOLE (306 patients)
METOCLOPRAMIDE (302 patients)
MORPHINE SULFATE (302 patients)
GLUCOPHAGE (300 patients)
ASCORBIC ACID (297 patients)
DEPAKOTE ER (295 patients)
LITHIUM CARBONATE (294 patients)
AVANDIA (291 patients)
REMERON (286 patients)
LIDOCAINE (286 patients)
AREDIA (284 patients)
ZITHROMAX (284 patients)
VINCRISTINE (283 patients)
ETOPOSIDE (283 patients)
FLUCONAZOLE (282 patients)
VITAMIN E (280 patients)
METOPROLOL (280 patients)
CALCIUM CARBONATE (279 patients)
PEPCID (278 patients)
BEVACIZUMAB (276 patients)
Most common side effects for patients taking ALMARL:
DEPRESSED LEVEL OF CONSCIOUSNESS (20 patients)
HALLUCINATION (15 patients)
FALL (13 patients)
HYPOGLYCAEMIA (13 patients)
PYREXIA (12 patients)
TREMOR (12 patients)
DIARRHOEA (11 patients)
HEPATIC FUNCTION ABNORMAL (11 patients)
PNEUMONIA (10 patients)
DYSARTHRIA (10 patients)
BLOOD CREATINE PHOSPHOKINASE INCREASED (9 patients)
RENAL FAILURE ACUTE (9 patients)
LIVER DISORDER (9 patients)
CEREBRAL INFARCTION (8 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (8 patients)
DRUG INEFFECTIVE (8 patients)
RENAL IMPAIRMENT (8 patients)
HYPONATRAEMIA (8 patients)
INTERSTITIAL LUNG DISEASE (8 patients)
JAUNDICE (8 patients)
OEDEMA PERIPHERAL (8 patients)
CONDITION AGGRAVATED (7 patients)
DELIRIUM (7 patients)
DYSPHAGIA (7 patients)
DYSPNOEA (7 patients)
HYPOAESTHESIA (7 patients)
RHABDOMYOLYSIS (7 patients)
VOMITING (6 patients)
DELUSION (6 patients)
RESPIRATORY FAILURE (6 patients)
DYSKINESIA (6 patients)
SOMNOLENCE (6 patients)
HEPATIC NEOPLASM MALIGNANT (6 patients)
HYPERGLYCAEMIA (6 patients)
HYPOKALAEMIA (6 patients)
MOVEMENT DISORDER (6 patients)
MUSCULAR WEAKNESS (6 patients)
WHITE BLOOD CELL COUNT INCREASED (5 patients)
BLADDER CANCER (5 patients)
BLOOD ANTIDIURETIC HORMONE INCREASED (5 patients)
RESTLESSNESS (5 patients)
BLOOD OSMOLARITY DECREASED (5 patients)
PLEURAL EFFUSION (5 patients)
C-REACTIVE PROTEIN INCREASED (5 patients)
CONVULSION (5 patients)
RENAL DISORDER (5 patients)
VITH NERVE PARALYSIS (5 patients)
INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION (5 patients)
INTESTINAL OBSTRUCTION (5 patients)
SEPSIS (5 patients)
ROAD TRAFFIC ACCIDENT (5 patients)
MUSCULOSKELETAL PAIN (5 patients)
NAUSEA (5 patients)
ANOREXIA (4 patients)
ATELECTASIS (4 patients)
ATRIAL FIBRILLATION (4 patients)
ATRIOVENTRICULAR BLOCK (4 patients)
BLOOD CREATININE INCREASED (4 patients)
BRADYCARDIA (4 patients)
CARDIAC FAILURE (4 patients)
CONSTIPATION (4 patients)
DECREASED APPETITE (4 patients)
DEHYDRATION (4 patients)
DIZZINESS (4 patients)
PLATELET COUNT DECREASED (4 patients)
PAIN (4 patients)
HYPERTENSION (4 patients)
HYPOTHYROIDISM (4 patients)
ILEUS (4 patients)
METABOLIC ACIDOSIS (4 patients)
SMALL INTESTINE CARCINOMA (4 patients)
URINE OSMOLARITY INCREASED (4 patients)
ABASIA (3 patients)
AGGRESSION (3 patients)
PRURITUS (3 patients)
ANAEMIA (3 patients)
PULMONARY ALVEOLAR HAEMORRHAGE (3 patients)
WHITE BLOOD CELL COUNT DECREASED (3 patients)
ASTHMA (3 patients)
BLOOD BILIRUBIN INCREASED (3 patients)
RENAL FAILURE (3 patients)
BLOOD PRESSURE DECREASED (3 patients)
BLOOD PRESSURE INCREASED (3 patients)
VASCULITIS (3 patients)
CAROTID ARTERY STENOSIS (3 patients)
THERAPEUTIC AGENT TOXICITY (3 patients)
CHILLS (3 patients)
CHROMATURIA (3 patients)
PETECHIAE (3 patients)
CHRONIC LYMPHOCYTIC LEUKAEMIA (3 patients)
PORIOMANIA (3 patients)
RENAL ARTERY STENOSIS (3 patients)
PANCYTOPENIA (3 patients)
DRUG ERUPTION (3 patients)
SUDDEN ONSET OF SLEEP (3 patients)
DRUG WITHDRAWAL SYNDROME (3 patients)
VERTIGO (3 patients)
EPILEPSY (3 patients)
FACE OEDEMA (3 patients)
VOLVULUS (3 patients)
GENERALISED OEDEMA (3 patients)
GINGIVAL BLEEDING (3 patients)
HAEMORRHAGE SUBCUTANEOUS (3 patients)
HALLUCINATION, VISUAL (3 patients)
PSYCHIATRIC SYMPTOM (3 patients)
HEART RATE DECREASED (3 patients)
HELICOBACTER TEST POSITIVE (3 patients)
HEPATITIS FULMINANT (3 patients)
HYPERKALAEMIA (3 patients)
HYPOTENSION (3 patients)
IDIOPATHIC THROMBOCYTOPENIC PURPURA (3 patients)
LOSS OF CONSCIOUSNESS (3 patients)
SENSORY DISTURBANCE (3 patients)
LYMPHOMA (3 patients)
MALAISE (3 patients)
MARKEDLY REDUCED DIETARY INTAKE (3 patients)
RENAL TUBULAR DISORDER (3 patients)
NEOPLASM MALIGNANT (3 patients)
SINUS ARREST (3 patients)
ABDOMINAL DISCOMFORT (2 patients)
ABDOMINAL PAIN (2 patients)
ACUTE MYELOID LEUKAEMIA (2 patients)
STOMACH MASS (2 patients)
PERSONALITY CHANGE (2 patients)
AGITATION (2 patients)
ALTERED STATE OF CONSCIOUSNESS (2 patients)
ANAPHYLACTOID REACTION (2 patients)
ANGER (2 patients)
PRODUCTIVE COUGH (2 patients)
RENAL CYST (2 patients)
APHASIA (2 patients)
ASTHENIA (2 patients)
ATRIOVENTRICULAR BLOCK COMPLETE (2 patients)
THIRST (2 patients)
PROSTATE CANCER (2 patients)
BLOOD AMYLASE INCREASED (2 patients)
BLOOD UREA INCREASED (2 patients)
BODY TEMPERATURE INCREASED (2 patients)
SPEECH DISORDER (2 patients)
TUMOUR LYSIS SYNDROME (2 patients)
CEREBRAL HAEMORRHAGE (2 patients)
CHEST X-RAY ABNORMAL (2 patients)
COLON CANCER (2 patients)
COMA HEPATIC (2 patients)
COMPLETED SUICIDE (2 patients)
CONTUSION (2 patients)
PERFORMANCE STATUS DECREASED (2 patients)
DEFAECATION URGENCY (2 patients)
DEMENTIA ALZHEIMER'S TYPE (2 patients)
RASH PRURITIC (2 patients)
DIABETIC KETOACIDOSIS (2 patients)
DRUG INTERACTION (2 patients)
DRUG LEVEL INCREASED (2 patients)
DYSPEPSIA (2 patients)
DYSSTASIA (2 patients)
ELECTROCARDIOGRAM QT PROLONGED (2 patients)
STEVENS-JOHNSON SYNDROME (2 patients)
EPULIS (2 patients)
EXTRAOCULAR MUSCLE PARESIS (2 patients)
FACIAL PARESIS (2 patients)
FEAR (2 patients)
FEBRILE NEUTROPENIA (2 patients)
FEMORAL NECK FRACTURE (2 patients)
FOOT FRACTURE (2 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (2 patients)
GANGRENE (2 patients)
GASTRIC ULCER HAEMORRHAGE (2 patients)
GINGIVAL HYPERTROPHY (2 patients)
GLOSSOPTOSIS (2 patients)
PLEURISY (2 patients)
PHRENIC NERVE PARALYSIS (2 patients)
HAEMATEMESIS (2 patients)
HAEMATURIA (2 patients)
HAEMOGLOBIN DECREASED (2 patients)
POLLAKIURIA (2 patients)
ORAL INTAKE REDUCED (2 patients)
HEPATIC CYST (2 patients)
HEPATIC ENCEPHALOPATHY (2 patients)
HEPATITIS (2 patients)
HYPERREFLEXIA (2 patients)
HYPERTONIA (2 patients)
HYPERURICAEMIA (2 patients)
RASH PAPULAR (2 patients)
INITIAL INSOMNIA (2 patients)
RETINAL OEDEMA (2 patients)
INTESTINAL FUNCTIONAL DISORDER (2 patients)
RESPIRATION ABNORMAL (2 patients)
IRRITABILITY (2 patients)
RIB FRACTURE (2 patients)
LEG AMPUTATION (2 patients)
LYMPHADENOPATHY (2 patients)
METABOLIC ALKALOSIS (2 patients)
ORAL HERPES (2 patients)
TAKAYASU'S ARTERITIS (2 patients)
MOUTH HAEMORRHAGE (2 patients)
UNRESPONSIVE TO STIMULI (2 patients)
TOXIC SKIN ERUPTION (2 patients)
NEPHROLITHIASIS (2 patients)
SUICIDE ATTEMPT (2 patients)
VENTRICULAR FIBRILLATION (2 patients)
NEUTROPHIL COUNT DECREASED (2 patients)
UPPER RESPIRATORY TRACT INFECTION (2 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (2 patients)
SHOCK HAEMORRHAGIC (2 patients)
ABDOMEN CRUSHING (1 patients)
CARDIAC FAILURE CONGESTIVE (1 patients)
EOSINOPHILIC PNEUMONIA ACUTE (1 patients)
ESSENTIAL TREMOR (1 patients)
WRONG TECHNIQUE IN DRUG USAGE PROCESS (1 patients)
FUNGAL INFECTION (1 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.


Recent FactMed Activity for ALMARL


Issue Description / Topic Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about CONVULSION and ALMARL, post it here. You may receive a response from a fellow patient - or a leading expert in the field.
Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking ALMARL, post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.
Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in ALMARL. This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.
We are currently accepting registration for ALMARL experts. If you are a healthcare provider experienced in prescribing ALMARL, please register here.

Your online appointment book for Colton Rentals & Services

© 2014 FactMed, Inc
Privacy Policy
Terms of Use